Background & Aims There is controversy over whether use of non-vitamin K antagonist oral
anticoagulants (NOACs) associates with increased risk of major gastrointestinal bleeding …

Aims Left ventricular thrombus (LVT) increases the risk of thrombotic events and mortality.
Vitamin K antagonists (VKAs) used to treat LVT have several known risks, as a result of …

Aims Left ventricular (LV) thrombus is increasingly detected in patients with and without
ischaemic heart disease due to the increased availability of cardiac magnetic resonance …

Clinicians accept that there are many unknowns when we make diagnostic and therapeutic
decisions. Acceptance of uncertainty is essential for the pursuit of the profession: bedside …

Introduction New oral anticoagulants are non-inferior compared with warfarin regarding
stroke prevention in atrial fibrillation, with similar or decreased risk of bleeding. However, it is …

Objective Warfarin is standard anticoagulation therapy for patients with a continuous-flow left
ventricular assist device (CF-LVAD). However, warfarin requires regular monitoring and …

Abstract Introduction/Purpose Mechanical thrombectomy (MT) for acute ischemic stroke (IS)
can be performed also in patients on anticoagulation therapy (AT); however, sufficient and …

Dronedarone may increase exposure and the risk of major bleeding when prescribed with a
direct oral anticoagulant (DOAC). This retrospective cohort study examined the risk of the …

Abstract Introduction Direct oral anticoagulants (DOACs) have been proven non-inferior or
superior to warfarin in preventing stroke and systemic embolism, with a lower risk of major …

Background Issues with laboratory measurement of dabigatran include: 1. Do coagulation
assays reflect dabigatran plasma concentrations? 2. Do samples from patients treated with …